Beijing Aosaikang's leulertinib tablets added to national medical insurance catalog

Beijing Aosaikang Pharmaceutical announced that its product, leulertinib tablets (trade name: Aoyixin), has been included in the "National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)." This inclusion, effective from January 1, 2026, to December 31, 2027, covers the drug as a Class B protein kinase inhibitor.

The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations and for patients with advanced NSCLC who have progressed after prior EGFR TKI treatment and are positive for the EGFR T790M mutation.

Clinical trials for leulertinib tablets showed a median progression-free survival (PFS) of 20.7 months, significantly outperforming gefitinib (9.7 months), reducing disease progression or death risk by 56%. For patients with measurable central nervous system (CNS) metastases, the drug demonstrated a median CNS PFS of 20.7 months, compared to 7.1 months for gefitinib, effectively reducing the risk of intracranial progression or death by 72%.

The inclusion in the medical insurance catalog is expected to enhance product accessibility and market promotion. However, the company noted that sales performance will be subject to market competition and sales expansion efforts, advising investors to exercise caution.